Navigation Links
Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
Date:10/25/2010

the Company's previous Phase 3 study as a key measure of durability following a 50-day course of treatment with orBec® (i.e., 30 days following cessation of treatment). The SUPPORTS trial is being conducted at major transplant centers throughout the US, Europe, and Australia and is expected to complete in the second half of 2011.  The trial is the subject of a Special Protocol Assessment (SPA) agreement that the Company reached with the US Food and Drug Administration (FDA).

orBec® was the subject of two prior randomized, double-blind, placebo-controlled clinical trials in acute GI GVHD. The first study was a 60-patient Phase 2 single-center clinical trial conducted at the Fred Hutchinson Cancer Research Center, which demonstrated statistical significance in its primary endpoint of controlling GI GVHD (p-value 0.02). The second study was a 129-patient pivotal Phase 3 multi-center clinical trial conducted at 16 leading bone marrow/stem cell transplant centers in the US and France. Although orBec® did not achieve statistical significance in the primary endpoint of its pivotal trial, namely median time-to-treatment failure through Day 50 (p-value 0.1177), orBec® did achieve statistical significance in other key secondary endpoints such as the proportion of patients free of GVHD at Day 50 (p-value 0.05) and Day 80 (p-value 0.005) and the median time to treatment failure through Day 80 (p-value 0.0226), as well as a 66% reduction in mortality among patients randomized to orBec® at 200 days post-transplant with only 5 patient (8%) deaths in the orBec® group compared to 16 patient (24%) deaths in the placebo group (p-value 0.0139).  At one year post-randomization in the Phase 3 trial, 18 patients (29%) in the orBec® group and 28 patients (42%) in the placebo group died within one year of randomization (46% reduction in mortality, p-value 0.04).

orBec® represents a first-of-its-kind oral, locally acting thera
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "China Orthopedic Instrument Industry Report, 2014-2017" report ... aging population and rising proportion of reimbursement for medical ... effectively released, with its scale presenting a CAGR of ... products are three product segments of orthopedic instruments in ...
(Date:8/29/2014)... 2014 Research and Markets has ... Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the ... landscape, and business performance of domestic major enterprises, as ...
(Date:8/29/2014)... 29, 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... it intends to release its financial results for the ... 2014 after market trading ends on Tuesday, September 9, ... call for 4:30 p.m. U.S. EDT on Tuesday, September ... to review the Company,s financial results, commercial partnerships, and ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... President Barack Obama was voted the most powerful person ... nation,s leading weekly healthcare business news magazine. It,s the second ... 100 Most Powerful People in Healthcare. "The passage ... spot for Obama," said Modern Healthcare Editor David ...
... Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior... -- ARDEE, Ireland, Aug. ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we ...
Cached Medicine Technology:Obama Named the Most Powerful Person in Healthcare for Second Consecutive Year 2Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 2Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 3Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 4Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 5Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 6Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 7Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 8Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 9Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 10Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 11
(Date:8/30/2014)... (PRWEB) August 30, 2014 Hundreds of ... claims continue to move forward in U.S. courts, Bernstein ... AstraZeneca PLC on July 31, 2014, Byetta and Bydureon ... 409 product liability claims that allege the drugs caused ... that many of these claims are pending in a ...
(Date:8/30/2014)... Continuing to meet the skin health ... the addition of a new doctor and office in ... leading-edge skin care in Grand Rapids since 1980 is ... a doctor, my passion is making sure my patients ... Dermatology, I’m better able to focus on my patients ...
(Date:8/30/2014)... CO (PRWEB) August 30, 2014 In today’s ... increasingly difficult to get. Snoring and sleep apnea (a medical ... rob people and their bed partners of the rest they ... 45% of the population snores and 20 million people in ... 10% have been diagnosed and treated; and of those treated, ...
(Date:8/30/2014)... PA (PRWEB) August 30, 2014 "My ... result of a car accident," said one of two ... muscle strain in her shoulder and neck area. She ... invented reduced pain and pressure, assisting in comfort and ... the patent-pending PILLOW CRADLE to support the head, neck ...
(Date:8/30/2014)... August 30, 2014 Market Research ... 2009-2019 is a professional and in-depth market survey ... report firstly reviews the basic information of Lab ... The report then explores global and China’s top ... capacity, production value, and market share etc. , ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Expanding Care at the Forefront of Dermatology 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4
... worst nightmare, a newborn baby going under the knife to ... the real work begins for parents. University of Alberta nursing ... brink as a former pediatric cardiology nurse; she wanted to ... not 100 per cent convinced that health-care professionals get what ...
... 26 The Providence Service,Corporation (Nasdaq: PRSC ) ... financial advisor. , In ... strategic,options relating to, among other things, delevering its debt, growing ... UBS,Investment Bank has been retained in connection with selling certain,non-strategic ...
... by phthalates in these products, experts say , , WEDNESDAY, ... common hairspray chemical while at work may be more ... urinary opening, a new report says. , Many ... products contain chemicals called phthalates, such as diethyl phthalate ...
... whose eyes are misaligned and point outward are ... by early adulthood, according to findings of a ... Pediatrics ( http://pediatrics.aappublications.org/cgi/content/full/122/5/1033 ), the official journal ... retrospective study examined the medical records of 407 ...
... and less time-consuming than in-person visits, study finds , , ... be as effective as face-to-face counseling in helping people ... Florida study included 234 obese women, ages 50 to ... All the women completed a six-month weight-loss program and ...
... practitioners from across the world are to share skills ... in South Africa, organised by the Wellcome Trust. , ... empower" will take place from 2-5 December at ... It will bring together practitioners working in the fields ...
Cached Medicine News:Health News:Parents are the unsung heroes 2Health News:Providence Service Corporation Retains UBS Investment Bank as its Financial Advisor in Connection With the Sale of Certain Non-Strategic Assets 2Health News:Over-the-Phone Weight Loss Counseling Works 2Health News:International workshop aims to boost public engagement work in developing countries 2Health News:International workshop aims to boost public engagement work in developing countries 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: